Vasculoprotective Effects of Vildagliptin. Focus on Atherogenesis

Vildagliptin is a representative of Dipeptidyl Peptidase-4 (DPP-4) inhibitors, antihyperglycemic drugs, approved for use as monotherapy and combination therapy in type 2 diabetes mellitus. By inhibiting enzymatic decomposition, DPP-4 inhibitors increase the half-life of incretins such as GLP-1 (Gluc...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Michał Wiciński, Karol Górski, Eryk Wódkiewicz, Maciej Walczak, Magdalena Nowaczewska, Bartosz Malinowski
Formato: Artigo
Lenguaje:Inglês
Publicado: MDPI AG 2020-03-01
Colección:International Journal of Molecular Sciences
Materias:
vildagliptin
endothelium
inflammation
atherogenesis
pathways
pharmacology
Acceso en línea:https://www.mdpi.com/1422-0067/21/7/2275
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares